1004 Venture Partners is a global specialist fund focused on investing in cutting-edge technologies that advance health and wellness, particularly in the area of healthy aging.
Key people at 1004 Venture Partners.
Key people at 1004 Venture Partners.
1004 Venture Partners is an early-stage investment firm dedicated to supporting startups that innovate in the field of healthy aging and longevity. Their mission centers on empowering entrepreneurs with transformative technologies that can revolutionize healthcare and improve quality of life as people age. The firm combines capital investment with deep mentorship and access to a strong network of industry professionals, investors, and key opinion leaders to help founders scale their businesses toward successful exits. Their investment philosophy emphasizes long-term impact on healthspan and wellness, addressing the growing global need for solutions that enable people to maintain dignity and reduce economic burdens associated with aging[1][3].
Founded by partners including Soyoung Park and David H. Crean, Ph.D., 1004 Venture Partners emerged from a passion for leveraging cutting-edge science and technology to tackle aging-related health challenges. David Crean brings over 30 years of life sciences and healthcare experience, with a personal connection to neurodegenerative diseases like Alzheimer’s, which informs the firm’s focus on diverse therapeutic approaches. Soyoung Park’s background in finance and startup operations in Silicon Valley inspired the founding vision to back transformative technologies that benefit the largest communities. The firm’s evolution reflects a commitment to not only funding but actively guiding startups through growth inflection points, driven by a belief in innovation’s power to address unmet medical needs[1][2][3].
1004 Venture Partners rides the wave of increasing global attention on age tech and health tech, driven by demographic shifts toward older populations and rising healthcare costs. The timing is critical as breakthroughs in biotechnology, medical devices, and digital health converge to create new opportunities for extending healthspan. Market forces such as unmet medical needs in neurodegenerative diseases and the economic imperative to reduce caregiving burdens favor investments in this sector. By fostering innovation in these areas, 1004 Venture Partners influences the broader ecosystem by accelerating the development of scalable solutions that can transform aging from a medical and social challenge into an opportunity for healthier longevity[1][2][3].
Looking ahead, 1004 Venture Partners is poised to deepen its impact by continuing to back diverse, cutting-edge approaches to aging-related health issues, including neurodegeneration and wellness technologies. Trends such as personalized medicine, AI-driven diagnostics, and integrated care models will shape their investment journey. As capital markets stabilize and innovation accelerates, the firm’s influence is likely to grow, helping to define the future of healthy aging globally. Their ongoing mentorship and network support will remain critical in turning scientific advances into accessible, life-enhancing products, fulfilling their mission to improve quality of life for aging populations while easing societal and economic pressures[1][2][3].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2022 | Playbook App | $6.0M Series A | — | Ludis Capital |
| Jan 1, 2021 | Tolago Hard Seltzer | $100K Seed | — | — |
| Mar 1, 2019 | California Tacos, Inc. | $200K Seed | — | — |
